M&A · Healthcare · Buyer's industry: In Vitro & In Vivo Diagnostic Substances
Lantheus Holdings, Inc. to acquire Evergreen Theragnostics
Announced Jan 28, 2025 · Closed Apr 1, 2025 · Private target
Deal value—
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash
Transaction
- Acquirer
- Lantheus Holdings, Inc. (LNTH)
- Target
- Evergreen Theragnostics
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- —
- Status
- Closed Apr 1, 2025
Deal protections
Not disclosed for private-company acquisitions.
Advisors
- To the acquirer
- Solomon Partners
- To the target
- Centerview
Classification
- Sector
- Healthcare
- Buyer's industry
- In Vitro & In Vivo Diagnostic Substances